CHChih-Fen Huang

Chih-Fen Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chih-Fen Huang has a total of 105 co-authors. Here are the top co-authors by number of shared publications:

  • Li-Jiuan Shen

    School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

    10 shared publications
  • Feipei Lai

    Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan

    6 shared publications
  • Fe-Lin Lin Wu

    Department of Pharmacy, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

    5 shared publications
  • Fei-Yuan Hsiao

    Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

    5 shared publications
  • Shin-Yi Lin

    Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

    5 shared publications
  • Sue-Hwa Lin

    Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

    5 shared publications

Latest Publications

  • Open Access

    Real‐World Edoxaban Concentrations in Older Patients Receiving Reduced‐Dose Regimens

    by Sung‐Chun Tang, Shin‐Yi Lin, Chih‐Hao Chen, Yen‐Bin Liu, Li‐Ting Ho, Ching‐Hua Kuo, Yu‐Fong Peng, Chih‐Fen Huang, Jiann‐Shing Jeng

    This study investigated real‐world edoxaban concentrations across different dosing regimens, with a specific focus on patients who met the inclusion criteria of low‐dose edoxaban for the Elder Care Atrial Fibrillation (ELDERCARE‐AF) trial. Patients with atrial fibrillation receiving edoxaban were enrolled to measure trough concentrations. The levels were compared with the expected therapeutic range (12–43 ng/mL) to define low or high concentrations. Data on ischemic stroke and systemic thromboembolism (SSE), and major bleeding, were collected prospectively. In total, 402 patients (77.2 ± 10.6 years; 52.2% men) were included. The SSE incidence was 1.22 (0.56–2.31) per 100 person years and was significantly associated with low edoxaban concentration (aHR, 4.13 [1.08–15.82]). Among patients meeting the ELDERCARE‐AF criteria ( n = 160), the use of the 15‐mg regimen (ELDER‐15 mg, n = 46) vs. the 30‐mg regimen (ELDER‐30 mg, n = 114) (aOR, 7.65 [2.92–20.09]), higher creatinine clearance (CrCL) (aOR, 1.05 [1.01–1.08]) and lower CHA 2 DS 2 ‐VA score (aOR, 0.69 [0.51, 0.95]) were significantly associated with low concentrations. In the ELDER‐15 mg group, patients with CrCL > 50 mL/min had more than 50% probability of exhibiting low drug concentrations. The incidence of SSE was numerically higher in the ELDER‐15 mg group than the ELDER‐30 mg group (2.34 [0.06–13.02] vs. 1.55 [0.32–4.52]), while major bleeding rates were similar (4.67 [0.57–16.89] vs. 5.15 [2.47–9.48]). In conclusion, low edoxaban concentrations have been associated with thromboembolic events. Among ELDERCARE‐AF‐eligible patients, the 15‐mg regimen results in underexposure to edoxaban, particularly when the CrCL exceeded 50 mL/min.


  • Open Access

    Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation

    by Shin‐Yi Lin, Yen‐Bing Liu, Li‐Ting Ho, Ching‐Hua Kuo, Yu‐Fong Peng, Chih‐Fen Huang, Sung‐Chun Tang, Jiann‐Shing Jeng

    This study aimed to analyze differences in the exposure‐response relationship for factor Xa inhibitors (FXaI) between patients aged ≥ 80 and < 80 years. Patients with atrial fibrillation (AF) taking rivaroxaban, apixaban, or edoxaban were enrolled, and a single steady‐state trough concentration was measured. FXaI concentrations were compared with the expected range reported in clinical trials to define high or low drug levels. The primary outcome was major bleeding, and the secondary outcome was ischemic stroke or transient ischemic attack (IS/TIA). From 2016 to 2023, 1,037 patients aged from 30 to 105 years were enrolled (average, 75.4 ± 10.0 years; 33.8% were aged ≥ 80 years). During a median follow‐up of 2.35 years, 48 major bleeding events and 32 IS/TIA events were observed. Although drug concentrations were similar between the two age groups, those aged ≥ 80 years with high FXaI levels experienced a greater increase in major bleeding risk compared to those aged < 80 years with high levels (aHR 6.47 [2.07, 20.28] vs. 3.45 [1.15, 10.30]). Additionally, patients aged ≥ 80 years without elevated FXaI levels also had a higher risk of major bleeding compared to those aged < 80 years without elevated levels (aHR 2.39 [1.20, 4.76]). While low FXaI concentrations were associated with IS/TIA, the risk was not significantly different across age groups. In conclusion, despite similar FXaI concentrations, patients aged ≥ 80 years have a higher baseline risk of major bleeding and experience a greater increase in bleeding risk at high drug levels compared to those aged < 80 years.


  • Open Access

    The effect of pharmacist-led medication therapy management in the multidisciplinary care of acute kidney injury survivors

    by Ting Wang, Hao-Cheng Kang, Chien-Chih Wu, Tsung-Lin Wu, Chih-Fen Huang, Vin-Cent Wu

    Background: The Acute Disease Quality Initiative advocates multidisciplinary care for the survivors of acute kidney injury (AKI). The bundled care strategy recognizes the role of pharmacists. However, their specific contributions in this context remain underexplored. Methods: This retrospective study examined the efficacy of pharmacist-led post-AKI pharmaceutical care in outpatient settings at a single center. Adults with recent AKI during hospitalization, maintaining an estimated glomerular filtration rate <45 mL/min/1.73 m2 postdischarge, were enrolled in a multidisciplinary team care program from March 2022 to January 2023, with a 6-month follow-up period. Pharmacist-delivered care adhered to international multidisciplinary consensus guidelines. Efficacy was evaluated by analyzing medication-related recommendations, medication adherence, nephrotoxic drug utilization, and renoprotective medication usage before and after the intervention. Results: A total of 40 patients were referred to the pharmacist-managed clinic. Of these, 33 patients (mean age, 63 ± 15 years; 60.6% male) attended the clinic. Nineteen patients completed follow-up visits. The pharmacist provided 14 medication-related recommendations to relevant physicians, with 10 of these recommendations (71.4%) being accepted. There was a significant decrease in the use of modifiable nephrotoxic drugs (p = 0.03). However, no significant improvements were noted in medication adherence or the utilization of renoprotective medications. Conclusion: Our study underscores the potential benefits of pharmacist-led post-AKI bundled care strategy in outpatient settings. We observed a significant reduction in the utilization of modifiable nephrotoxic drugs, indicating the effectiveness of pharmacist interventions in optimizing medication regimens to mitigate renal harm.


  • Association Between Apixaban Concentration and Clinical Outcomes in Asians With Atrial Fibrillation

    by Shin-Yi Lin, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng


  • Open Access

    The Impact of Pharmacist‐Managed Service on Warfarin Therapy in Patients after Mechanical Valve Replacement

    by Chia-Wei Wu, Chien-Chih Wu, Chien-Hao Chen, Shin-Yi Lin, Ron-Bin Hsu, Chih-Fen Huang

    Objective. To evaluate the impact of pharmacist interventions on international normalized ratio (INR) control during the warfarin initiation phase after mechanical valve replacement. Methods. This was a retrospective cohort study conducted in a cardiovascular surgery ward in a tertiary hospital from August 1, 2015, to July 31, 2019. Patients aged ≥20 years who were admitted for mechanical valve replacement were enrolled in this study and further classified into conventional and pharmacist‐managed warfarin therapy (PMWT) groups. All participants were prospectively followed up until the first outpatient appointment after valve replacement. The effectiveness outcomes were time in therapeutic range (TTR), time to therapeutic INR, number of patients with therapeutic INR at discharge and at first outpatient appointment, and length of hospital stay. The safety outcome was the number of patients with any supratherapeutic INR during the hospital stay. Multivariate logistic regression analyses were also used to determine the predictors of a therapeutic INR at discharge or with any supratherapeutic INR during admission. Results. A total of 39 and 33 patients were enrolled in the conventional and PMWT groups, respectively. At discharge, 18 patients (46.2%) in the conventional group and 24 patients (72.7%) in the PMWT group had achieved the therapeutic INR (P = 0.023). Compared to the conventional group, fewer patients in the PMWT group had supratherapeutic INR during hospital stay (35.9% vs. 9.0%, P = 0.008). No significant differences were found in TTR, time to therapeutic INR, number of patients with therapeutic INR at return appointment, and length of stay between the study groups. In the multivariate regression analyses, PMWT predicted achieving therapeutic INR at discharge (odds ratio (OR) and 95% confidence interval (CI), 3.14 [1.08–9.14]) and was inversely associated with supratherapeutic INRs during admission (OR = 0.21 [0.05–0.82]). Conclusions. Among patients admitted for mechanical valve replacement, the implementation of PMWT was associated with optimal therapeutic INR at discharge and no supratherapeutic INR during admission. Therefore, pharmacist participation is essential for improving the quality of warfarin therapy.


  • Effects of a pharmacist-managed anticoagulation outpatient clinic in Taiwan: evaluation of patient knowledge, satisfaction, and clinical outcomes

    by Shin-Yi Lin, Yi-Wen Chen, Hao-Cheng Kang, Yee-Jen Wu, Pin-Zi Chen, Chia-Wei Wu, Chii-Shan Lin, Fe-Lin Lin Wu, Li-Jiuan Shen, Yen-Ming Huang, et al.

    The study aimed to evaluate the improvement of patient knowledge of warfarin use, satisfaction with pharmacists, and the quality of international normalized ratio (INR) control after the implementa...


  • Open Access

    Development of A Drug Early Warning System Model for Cardiac Arrest Using Deep Learning: Retrospective Cohort Study (Preprint)

    by Hsiao-Ko Chang, Hui-Chih Wang, Chih-Fen Huang, Feipei Lai

    BACKGROUND In most of Taiwan’s medical institutions, congestion is a serious problem for emergency departments. Due to a lack of beds, patients spend more time in emergency retention zones, which make it difficult to detect cardiac arrest (CA). OBJECTIVE We seek to develop a Drug Early Warning System Model (DEWSM), it included drug injections and vital signs as this research important features. We use it to predict cardiac arrest in emergency departments via drug classification and medical expert suggestion. METHODS We propose this new model for detecting cardiac arrest via drug classification and by using a sliding window; we apply learning-based algorithms to time-series data for a DEWSM. By treating drug features as a dynamic time-series factor for cardiopulmonary resuscitation (CPR) patients, we increase sensitivity, reduce false alarm rates and mortality, and increase the model’s accuracy. To evaluate the proposed model, we use the area under the receiver operating characteristic curve (AUROC). RESULTS Four important findings are as follows: (1) We identify the most important drug predictors: bits (intravenous therapy), and replenishers and regulators of water and electrolytes (fluid and electrolyte supplement). The best AUROC of bits is 85%, it means the medical expert suggest the drug features: bits, it will affect the vital signs, and then the evaluate this model correctly classified patients with CPR reach 85%; that of replenishers and regulators of water and electrolytes is 86%. These two features are the most influential of the drug features in the task. (2) We verify feature selection, in which accounting for drugs improve the accuracy: In Task 1, the best AUROC of vital signs is 77%, and that of all features is 86%. In Task 2, the best AUROC of all features is 85%, which demonstrates that thus accounting for the drugs significantly affects prediction. (3) We use a better model: For traditional machine learning, this study adds a new AI technology: the long short-term memory (LSTM) model with the best time-series accuracy, comparable to the traditional random forest (RF) model; the two AUROC measures are 85%. It can be seen that the use of new AI technology will achieve better results, currently comparable to the accuracy of traditional common RF, and the LSTM model can be adjusted in the future to obtain better results. (4) We determine whether the event can be predicted beforehand: The best classifier is still an RF model, in which the observational starting time is 4 hours before the CPR event. Although the accuracy is impaired, the predictive accuracy still reaches 70%. Therefore, we believe that CPR events can be predicted four hours before the event. CONCLUSIONS This paper uses a sliding window to account for dynamic time-series data consisting of the patient’s vital signs and drug injections. The National Early Warning Score (NEWS) only focuses on the score of vital signs, and does not include factors related to drug injections. In this study, the experimental results of adding the drug injections are better than only vital signs. In a comparison with NEWS, we improve predictive accuracy via feature selection, which includes drugs as features. In addition, we use traditional machine learning methods and deep learning (using LSTM method as the main processing time series data) as the basis for comparison of this research. The proposed DEWSM, which offers 4-hour predictions, is better than the NEWS in the literature. This also confirms that the doctor’s heuristic rules are consistent with the results found by machine learning algorithms.

  • Open Access

    Development of A Pharmaceutical Early Warning Scoring Model for Cardiac Arrest Using Deep Learning: Retrospective Cohort Study (Preprint)

    by Hsiao-Ko Chang, Hui-Chih Wang, Chih-Fen Huang, Feipei Lai

    BACKGROUND In most of Taiwan’s medical institutions, congestion is a serious problem for emergency departments. Due to a lack of beds, patients spend more time in emergency retention zones, which make it difficult to detect cardiac arrest (CA). OBJECTIVE We seek to develop a pharmaceutical early warning model to predict cardiac arrest in emergency departments via drug classification and medical expert suggestion. METHODS We propose a new early warning score model for detecting cardiac arrest via pharmaceutical classification and by using a sliding window; we apply learning-based algorithms to time-series data for a Pharmaceutical Early Warning Scoring Model (PEWSM). By treating pharmaceutical features as a dynamic time-series factor for cardiopulmonary resuscitation (CPR) patients, we increase sensitivity, reduce false alarm rates and mortality, and increase the model’s accuracy. To evaluate the proposed model we use the area under the receiver operating characteristic curve (AUROC). RESULTS Four important findings are as follows: (1) We identify the most important drug predictors: bits, and replenishers and regulators of water and electrolytes. The best AUROC of bits is 85%; that of replenishers and regulators of water and electrolytes is 86%. These two features are the most influential of the drug features in the task. (2) We verify feature selection, in which accounting for drugs improve the accuracy: In Task 1, the best AUROC of vital signs is 77%, and that of all features is 86%. In Task 2, the best AUROC of all features is 85%, which demonstrates that thus accounting for the drugs significantly affects prediction. (3) We use a better model: For traditional machine learning, this study adds a new AI technology: the long short-term memory (LSTM) model with the best time-series accuracy, comparable to the traditional random forest (RF) model; the two AUROC measures are 85%. (4) We determine whether the event can be predicted beforehand: The best classifier is still an RF model, in which the observational starting time is 4 hours before the CPR event. Although the accuracy is impaired, the predictive accuracy still reaches 70%. Therefore, we believe that CPR events can be predicted four hours before the event. CONCLUSIONS This paper uses a sliding window to account for dynamic time-series data consisting of the patient’s vital signs and drug injections. In a comparison with NEWS, we improve predictive accuracy via feature selection, which includes drugs as features. In addition, LSTM yields better performance with time-series data. The proposed PEWSM, which offers 4-hour predictions, is better than the National Early Warning Score (NEWS) in the literature. This also confirms that the doctor’s heuristic rules are consistent with the results found by machine learning algorithms.

  • Open Access

    A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non–Vitamin K Antagonist Oral Anticoagulants and Warfarin

    by Fong-Ci Lin, Shih-Tsung Huang, Rung Ji Shang, Chi-Chuan Wang, Fei-Yuan Hsiao, Fang-Ju Lin, Mei-Shu Lin, Kuan-Yu Hung, Jui Wang, Li-Jiuan Shen, et al.

    Background: Conventional systems of drug surveillance lack a seamless workflow, which makes it crucial to have an active drug surveillance system that proactively assesses adverse drug events. Objective: The aim of this study was to develop a seamless, Web-based workflow for comparing the safety and effectiveness of drugs in a database of electronic medical records. Methods: We proposed a comprehensive integration process for cohort surveillance using the National Taiwan University Hospital Clinical Surveillance System (NCSS). We studied a practical application of the NCSS that evaluates the drug safety and effectiveness of novel oral anticoagulants (NOACs) and warfarin by cohort tree analysis in an efficient and interoperable platform. Results: We demonstrated a practical example of investigating the differences in effectiveness and safety between NOACs and warfarin in patients with nonvalvular atrial fibrillation (AF) using the NCSS. We efficiently identified 2357 patients with nonvalvular AF with newly prescribed oral anticoagulants between 2010 and 2015 and further developed 1 main cohort and 2 subcohorts for separately measuring ischemic stroke as the clinical effectiveness outcome and intracranial hemorrhage (ICH) as the safety outcome. In the subcohort of ischemic stroke, NOAC users exhibited a significantly lower risk of ischemic stroke than warfarin users after adjusting for age, sex, comorbidity, and comedication in an intention-to-treat (ITT) analysis (P=.01) but did not exhibit a significantly distinct risk in an as-treated (AT) analysis (P=.12) after the 2-year follow-up. In the subcohort of ICH, NOAC users did not exhibit a different risk of ICH both in ITT (P=.68) and AT analyses (P=.15). Conclusions: With a seamless and Web-based workflow, the NCSS can serve the critical role of forming associations between evidence and the real world at a medical center in Taiwan.


  • Open Access

    Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study

    by Tzu-Lan Huang, Fei-Yuan Hsiao, Chih-Kang Chiang, Li-Jiuan Shen, Chih-Fen Huang

    Cardiovascular events associated with oral hypoglycemic agents (OHAs) have raised significant safety concerns. This study assessed the association between dipeptidyl peptidase-4 inhibitors (DPP-4i) and the risk of cardiovascular events in patients with type 2 diabetes mellitus with or without chronic kidney disease (CKD). A retrospective cohort study using Taiwan’s National Health Insurance Research Database. Our study included patients with type 2 diabetes who received OHAs between March 1, 2009, and December 31, 2012. All eligible subjects were classified into CKD and non-CKD cohorts and further categorized as the DPP-4i and non-DPP-4i users in each cohort. The DPP-4i and non-DPP-4i groups were matched 1:1 by propensity score to attenuate potential selection bias. Propensity score was estimated by logistic regression, using demographics, co-medications, comorbidities. and adapted diabetic complication severity index at baseline. Outcomes of interest included a composite endpoint of ischemic stroke, myocardial infarction, cardiovascular death (major adverse cardiac events [MACE]), and hospitalization for heart failure (hHF). COX proportional hazard models were applied to examine the association between DPP-4i and outcomes of interest. We identified 37,641 and 87,604 patients with type 2 diabetes with and without CKD, respectively. After propensity score matching, 8,213 pairs of CKD patients and 12,313 pairs of non-CKD patients were included for analysis. In the CKD cohort, DPP-4i were associated with a 25% increased risk of hHF (DPP-4i vs. non-DPP-4i incidence/1,000 person-years: 15.0 vs. 9.9, HR = 1.25; 95% CI 1.01–1.54, p = 0.037) but not with the risk of MACE (HR = 0.89, p = 0.144). In the non-CKD cohort, DPP-4i were associated with a lower risk of MACE (DPP-4i vs. non-DPP-4i incidence/1,000 person-years: 9.8 vs. 12.6 HR = 0.73; 95% CI 0.61–0.87, p = 0.0007), but not the risk of hHF (HR = 1.09, p = 0.631). DPP-4i were found to be associated with decreased risk of MACE in the non-CKD cohort in our study. However, DPP-4i were associated with increased risk of hHF in the CKD cohort. DPP-4i in the CKD cohort should be used cautiously.